南京科佰生物科技有限公司
主營產(chǎn)品: atcc代理,ATCC細(xì)胞系,ATCC細(xì)胞株,ATCC細(xì)胞庫購買 |
聯(lián)系電話
南京科佰生物科技有限公司
主營產(chǎn)品: atcc代理,ATCC細(xì)胞系,ATCC細(xì)胞株,ATCC細(xì)胞庫購買 |
聯(lián)系電話
參考價(jià) | 面議 |
更新時(shí)間:2022-08-04 10:28:34瀏覽次數(shù):617
聯(lián)系我們時(shí)請說明是化工儀器網(wǎng)上看到的信息,謝謝!
供貨周期 | 現(xiàn)貨 | 規(guī)格 | T-25 Flask |
---|---|---|---|
貨號 | CBP74154 | 應(yīng)用領(lǐng)域 | 生物產(chǎn)業(yè) |
主要用途 | 僅限科研使用 |
CBP74154 | |
I. Background | |
SIRP alpha protein, or Signal regulatory proteinalpha (SIRP-α), also known as Tyrosine protein phosphatase non-receptor type substrate 1, CD172a, Bit, and MyD-1, GenBank Accession No. NM_080792, a.a. 27-370, with C-terminal Avi and His tags, MW 40.3 kDa*. This SIRP alpha protein acts as a receptor for CD47; a.a. 27-370 correspond to the extracellular portion of SIRP-α. *Note: SIRP-α is heavily glycosylated, resulting in higher molecular weight. The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. PD-1 ligands are found on most cancers, and the PD-1:PD-L1/2 interaction inhibits T-cell activity and enables cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes | |
II. Introduction | |
Expressed gene: | SIRPɑ、PD-1 |
Stability: | 32 passages(in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Synonym(s): | SIRPɑ、PD-1 |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | RPMI-1640+10%FBS+2ug/ml puromycin+ 5ug/ml blasticidin+200ug/ml hygromycin |
Mycoplasma Testing: | Negative |
Storage: | Liquid nitrogen |
Application(s): | Functional(Report Gene) Assay |
III. Representative Data | |
Figure 1. Dose response of Blocking Antibodies in SIRPα/PD-1 Dual Effector Reporter Cells(C18) With CD47/PD-L1 Dual Target Cells. | |